Los Angeles Capital Management
SMMT icon

Los Angeles Capital Management’s Summit Therapeutics SMMT Stock Holding History

Los Angeles Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.49K Hold
514
– – ﹤0.01% 2030
2026
Q1 		$9.74K Buy
+514
New +$8.31K ﹤0.01% 1960

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Los Angeles Capital Management's SMMT Position: Q2 2026 in Review

Los Angeles Capital Management held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 514 shares worth $7.49K. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Los Angeles Capital Management first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.74K in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Los Angeles Capital Management held 514 shares of Summit Therapeutics worth $7.49K as of Q2 2026.
  • Los Angeles Capital Management left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2030 holding.
  • Los Angeles Capital Management first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Los Angeles Capital Management's Summit Therapeutics position peaked at $9.74K in Q1 2026.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.